BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hong C, Byrne NJ, Zamlynny B, Tummala S, Xiao L, Shipman JM, Partridge AT, Minnick C, Breslin MJ, Rudd MT, Stachel SJ, Rada VL, Kern JC, Armacost KA, Hollingsworth SA, O'Brien JA, Hall DL, McDonald TP, Strickland C, Brooun A, Soisson SM, Hollenstein K. Structures of active-state orexin receptor 2 rationalize peptide and small-molecule agonist recognition and receptor activation. Nat Commun 2021;12:815. [PMID: 33547286 DOI: 10.1038/s41467-021-21087-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Iio K, Saitoh T, Ohshita R, Hino T, Amezawa M, Takayama Y, Nagumo Y, Yamamoto N, Kutsumura N, Irukayama-tomobe Y, Ishikawa Y, Tanimura R, Yanagisawa M, Nagase H. Discovery of Orexin 2 Receptor Selective and Dual Orexin Receptor Agonists based on the Tetralin Structure: Switching of Receptor Selectivity by Chirality on the Tetralin Ring. Bioorganic & Medicinal Chemistry Letters 2022. [DOI: 10.1016/j.bmcl.2022.128555] [Reference Citation Analysis]
2 Couvineau A, Voisin T, Nicole P, Gratio V, Blais A. Orexins: A promising target to digestive cancers, inflammation, obesity and metabolism dysfunctions. World J Gastroenterol 2021; 27(44): 7582-7596 [PMID: 34908800 DOI: 10.3748/wjg.v27.i44.7582] [Reference Citation Analysis]
3 Harris JA, Faust B, Gondin AB, Dämgen MA, Suomivuori CM, Veldhuis NA, Cheng Y, Dror RO, Thal DM, Manglik A. Selective G protein signaling driven by substance P-neurokinin receptor dynamics. Nat Chem Biol 2021. [PMID: 34711980 DOI: 10.1038/s41589-021-00890-8] [Reference Citation Analysis]
4 Zhang D, Perrey DA, Decker AM, Langston TL, Mavanji V, Harris DL, Kotz CM, Zhang Y. Discovery of Arylsulfonamides as Dual Orexin Receptor Agonists. J Med Chem 2021;64:8806-25. [PMID: 34101446 DOI: 10.1021/acs.jmedchem.1c00841] [Reference Citation Analysis]
5 Tian Y, Qin Z, Han Y. Suvorexant with or without ramelteon to prevent delirium: a systematic review and meta-analysis. Psychogeriatrics 2021. [PMID: 34881812 DOI: 10.1111/psyg.12792] [Reference Citation Analysis]
6 Alain C, Pascal N, Valérie G, Thierry V. Orexins/Hypocretins and Cancer: A Neuropeptide as Emerging Target. Molecules 2021;26:4849. [PMID: 34443437 DOI: 10.3390/molecules26164849] [Reference Citation Analysis]
7 Thom C, Ehrenmann J, Vacca S, Waltenspühl Y, Schöppe J, Medalia O, Plückthun A. Structures of neurokinin 1 receptor in complex with Gq and Gs proteins reveal substance P binding mode and unique activation features. Sci Adv 2021;7:eabk2872. [PMID: 34878828 DOI: 10.1126/sciadv.abk2872] [Reference Citation Analysis]
8 Hino T, Saitoh T, Nagumo Y, Yamamoto N, Kutsumura N, Irukayama-Tomobe Y, Ishikawa Y, Tanimura R, Yanagisawa M, Nagase H. Design and synthesis of novel orexin 2 receptor agonists based on naphthalene skeleton. Bioorg Med Chem Lett 2022;:128530. [PMID: 35007725 DOI: 10.1016/j.bmcl.2022.128530] [Reference Citation Analysis]
9 Mobbs JI, Belousoff MJ, Harikumar KG, Piper SJ, Xu X, Furness SGB, Venugopal H, Christopoulos A, Danev R, Wootten D, Thal DM, Miller LJ, Sexton PM. Structures of the human cholecystokinin 1 (CCK1) receptor bound to Gs and Gq mimetic proteins provide insight into mechanisms of G protein selectivity. PLoS Biol 2021;19:e3001295. [PMID: 34086670 DOI: 10.1371/journal.pbio.3001295] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
10 Liu Q, Yang D, Zhuang Y, Croll TI, Cai X, Dai A, He X, Duan J, Yin W, Ye C, Zhou F, Wu B, Zhao Q, Xu HE, Wang MW, Jiang Y. Ligand recognition and G-protein coupling selectivity of cholecystokinin A receptor. Nat Chem Biol 2021;17:1238-44. [PMID: 34556862 DOI: 10.1038/s41589-021-00841-3] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]